Searched for
DIIACHI SANKYO
Biocon puts arthritis drug on backburnerBiocon and Mylan have been working for a decade on a biosimilar version of the drug, originally sold by Amgen under brand name Enbrel.- Fortis Healthcare signs definitive agreement to acquire assets of RHT Health TrustFortis board aimed at consolidating the entire Indian asset portfolio (12 clinical establishments, 4 greenfield clinical establishment and ...
- Japanese companies make cautious return to Indian pharma marketOther drug companies whose acquisition went southwards included Mitsui & Co, which acquired a significant stake in Arch Pharma.
- Hold Daiichi for contempt of court responsible for leak: RH HoldingsThe company’s statement came in the wake of a news report that said Ranbaxy’s promoters duped Japanese drugmaker Diiachi Sankyo by withhold...
- Sun Pharma acquires US-based PharmalucenceThis acquisition comes months after Sun Pharma announced a deal to buy Ranbaxy Laboratories from Japan's Diiachi Sankyo for $3.2 billion in...
- Ranbaxy shares jump on approval of generic drug DiovanRanbaxy should be able to generate $190 million of sales and an after-tax profit of $100 million during 180 days, said a research analyst.
- Sun Pharma denies insider trading charges in Ranbaxy dealSun Pharma denied insider trading charges against Silverstreet Developers- its wholly owned arm - in the $4 bn acquisition deal of Ranbaxy ...
- Dilip Shanghvi, Sun Pharma promoter, a pharma maven with midas touchHis staff call him India's most aggressive promoter whose calm demeanour shadows his killer instincts when it comes to splurging on riskies...
- Sun Pharma to buy Ranbaxy in $3.2 bn deal“This is the biggest deal we have done, but not the most difficult one,” said Sun Pharma chairman Dilip Shanghvi.
- Ranbaxy episode to hit drugs carrying ‘India’ label; tough to secure new contractsDrug makers worry that the Ranbaxy example puts the entire Indian industry under the bracket of “dirty” manufacturers.
Load More
